133 related articles for article (PubMed ID: 25497965)
1. Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach.
Matsufuji T; Shimada K; Kobayashi S; Ichikawa M; Kawamura A; Fujimoto T; Arita T; Hara T; Konishi M; Abe-Ohya R; Izumi M; Sogawa Y; Nagai Y; Yoshida K; Abe Y; Kimura T; Takahashi H
Bioorg Med Chem; 2015 Jan; 23(1):89-104. PubMed ID: 25497965
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel imidazol-1-ylacetic acid derivatives as non-brain penetrant bombesin receptor subtype-3 (BRS-3) agonists.
Kiyotsuka Y; Shimada K; Kobayashi S; Suzuki M; Akiu M; Asano M; Sogawa Y; Hara T; Konishi M; Abe-Ohya R; Izumi M; Nagai Y; Yoshida K; Abe Y; Takamori H; Takahashi H
Bioorg Med Chem Lett; 2016 Sep; 26(17):4205-10. PubMed ID: 27491709
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration.
Matsufuji T; Shimada K; Kobayashi S; Kawamura A; Fujimoto T; Arita T; Hara T; Konishi M; Abe-Ohya R; Izumi M; Sogawa Y; Nagai Y; Yoshida K; Takahashi H
Bioorg Med Chem Lett; 2014 Feb; 24(3):750-5. PubMed ID: 24412111
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
Hadden M; Goodman A; Guo C; Guzzo PR; Henderson AJ; Pattamana K; Ruenz M; Sargent BJ; Swenson B; Yet L; Liu J; He S; Sebhat IK; Lin LS; Tamvakopoulos C; Peng Q; Kan Y; Palyha O; Kelly TM; Guan XM; Metzger JM; Reitman ML; Nargund RP
Bioorg Med Chem Lett; 2010 May; 20(9):2912-5. PubMed ID: 20347296
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.
Guo C; Guzzo PR; Hadden M; Sargent BJ; Yet L; Kan Y; Palyha O; Kelly TM; Guan X; Rosko K; Gagen K; Metzger JM; Dragovic J; Lyons K; Lin LS; Nargund RP
Bioorg Med Chem Lett; 2010 May; 20(9):2785-9. PubMed ID: 20371178
[TBL] [Abstract][Full Text] [Related]
6. Novel chiral-diazepines function as specific, selective receptor agonists with variable coupling and species variability in human, mouse and rat BRS-3 receptor cells.
Ramos-Álvarez I; Nakamura T; Mantey SA; Moreno P; Nuche-Berenguer B; Jensen RT
Peptides; 2016 Jan; 75():8-17. PubMed ID: 26524625
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
Liu J; He S; Jian T; Dobbelaar PH; Sebhat IK; Lin LS; Goodman A; Guo C; Guzzo PR; Hadden M; Henderson AJ; Pattamana K; Ruenz M; Sargent BJ; Swenson B; Yet L; Tamvakopoulos C; Peng Q; Pan J; Kan Y; Palyha O; Kelly TM; Guan XM; Howard AD; Marsh DJ; Metzger JM; Reitman ML; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2010 Apr; 20(7):2074-7. PubMed ID: 20219372
[TBL] [Abstract][Full Text] [Related]
8. Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.
Guan XM; Metzger JM; Yang L; Raustad KA; Wang SP; Spann SK; Kosinski JA; Yu H; Shearman LP; Faidley TD; Palyha O; Kan Y; Kelly TM; Sebhat I; Lin LS; Dragovic J; Lyons KA; Craw S; Nargund RP; Marsh DJ; Strack AM; Reitman ML
J Pharmacol Exp Ther; 2011 Feb; 336(2):356-64. PubMed ID: 21036912
[TBL] [Abstract][Full Text] [Related]
9. Body temperature as a mouse pharmacodynamic response to bombesin receptor subtype-3 agonists and other potential obesity treatments.
Metzger JM; Gagen K; Raustad KA; Yang L; White A; Wang SP; Craw S; Liu P; Lanza T; Lin LS; Nargund RP; Guan XM; Strack AM; Reitman ML
Am J Physiol Endocrinol Metab; 2010 Nov; 299(5):E816-24. PubMed ID: 20807840
[TBL] [Abstract][Full Text] [Related]
10. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity.
Guan XM; Chen H; Dobbelaar PH; Dong Y; Fong TM; Gagen K; Gorski J; He S; Howard AD; Jian T; Jiang M; Kan Y; Kelly TM; Kosinski J; Lin LS; Liu J; Marsh DJ; Metzger JM; Miller R; Nargund RP; Palyha O; Shearman L; Shen Z; Stearns R; Strack AM; Stribling S; Tang YS; Wang SP; White A; Yu H; Reitman ML
Cell Metab; 2010 Feb; 11(2):101-12. PubMed ID: 20096642
[TBL] [Abstract][Full Text] [Related]
11. Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.
Yang HY; Tae J; Seo YW; Kim YJ; Im HY; Choi GD; Cho H; Park WK; Kwon OS; Cho YS; Ko M; Jang H; Lee J; Choi K; Kim CH; Lee J; Pae AN
Eur J Med Chem; 2013 May; 63():558-69. PubMed ID: 23537943
[TBL] [Abstract][Full Text] [Related]
12. A Selective Bombesin Receptor Subtype 3 Agonist Promotes Weight Loss in Male Diet-Induced-Obese Rats With Circadian Rhythm Change.
Nio Y; Hotta N; Maruyama M; Hamagami K; Nagi T; Funata M; Sakamoto J; Nakakariya M; Amano N; Okawa T; Arikawa Y; Sasaki S; Okuda S; Kasai S; Habata Y; Nagisa Y
Endocrinology; 2017 May; 158(5):1298-1313. PubMed ID: 28324017
[TBL] [Abstract][Full Text] [Related]
13. Appetite-modifying effects of bombesin receptor subtype-3 agonists.
Majumdar ID; Weber HC
Handb Exp Pharmacol; 2012; (209):405-32. PubMed ID: 22249826
[TBL] [Abstract][Full Text] [Related]
14. Biology and pharmacology of bombesin receptor subtype-3.
Majumdar ID; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2012 Feb; 19(1):3-7. PubMed ID: 22157398
[TBL] [Abstract][Full Text] [Related]
15. Pyridinesulfonylureas and pyridinesulfonamides as selective bombesin receptor subtype-3 (BRS-3) agonists.
Lo MM; Chobanian HR; Palyha O; Kan Y; Kelly TM; Guan XM; Reitman ML; Dragovic J; Lyons KA; Nargund RP; Lin LS
Bioorg Med Chem Lett; 2011 Apr; 21(7):2040-3. PubMed ID: 21354793
[TBL] [Abstract][Full Text] [Related]
16. Melanin-concentrating hormone receptor 1 antagonists: synthesis, structure-activity relationship, docking studies, and biological evaluation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.
Kasai S; Kamaura M; Kamata M; Aso K; Ogino H; Nakano Y; Watanabe K; Kaisho T; Tawada M; Nagisa Y; Takekawa S; Kato K; Suzuki N; Ishihara Y
Bioorg Med Chem; 2011 Nov; 19(21):6261-73. PubMed ID: 21975069
[TBL] [Abstract][Full Text] [Related]
17. Discovery of high affinity bombesin receptor subtype 3 agonists.
Wu JM; Nitecki DE; Biancalana S; Feldman RI
Mol Pharmacol; 1996 Nov; 50(5):1355-63. PubMed ID: 8913368
[TBL] [Abstract][Full Text] [Related]
18. The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.
Chobanian HR; Guo Y; Liu P; Lanza TJ; Chioda M; Chang L; Kelly TM; Kan Y; Palyha O; Guan XM; Marsh DJ; Metzger JM; Raustad K; Wang SP; Strack AM; Gorski JN; Miller R; Pang J; Lyons K; Dragovic J; Ning JG; Schafer WA; Welch CJ; Gong X; Gao YD; Hornak V; Reitman ML; Nargund RP; Lin LS
Bioorg Med Chem; 2012 May; 20(9):2845-9. PubMed ID: 22494842
[TBL] [Abstract][Full Text] [Related]
19. Bombesin receptor subtype 3 as a potential target for obesity and diabetes.
González N; Moreno P; Jensen RT
Expert Opin Ther Targets; 2015; 19(9):1153-70. PubMed ID: 26066663
[TBL] [Abstract][Full Text] [Related]
20. Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
Ham J; Hwang H; Kim E; Kim JA; Cho SJ; Ko J; Lee W; Lee J; Holla H; Banerjee J; Kim S; Yang I; Lee HJ; Shin K; Choi H; Nam SJ; Tak J; Hahn D; Oh T; Won DH; Lee TG; Choi J; Park MS; Seok C; Chin J; Kang H
Eur J Med Chem; 2012 Jul; 53():190-202. PubMed ID: 22534184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
